Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Danazol and antithrombin III deficiency].

M Lucchi1, S Bilancini

  • 1Centro Studi Malattie Vascolari, Frosinone, Italie.

Journal Des Maladies Vasculaires
|January 1, 1990
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Acetylcholinesterase inhibitors are ineffective in MuSK-antibody positive myasthenia gravis: Results of a study on 202 patients.

Journal of the neurological sciences·2024
Same author

Management of patients with extensive locally advanced thyroid cancer: results of multimodal treatments.

Journal of endocrinological investigation·2023
Same author

Presence, enzymatic activity, and subcellular localization of paraoxonases 1, 2, and 3 in human lung tissues.

Life sciences·2022
Same author

Paraneoplastic Raynaud's phenomenon associated to astrocytoma.

Journal de medecine vasculaire·2020
Same author

Histo-cytological diagnostic accuracy in lung cancer.

Cytopathology : official journal of the British Society for Clinical Cytology·2013
Same author

Detection and therapeutic implications of c-Met mutations in small cell lung cancer and neuroendocrine tumors.

Current pharmaceutical design·2012

This study found that Danazol treatment significantly increased antithrombin III levels in patients with sporadic deficiency. These elevated levels persisted even after discontinuing the drug, suggesting a potential long-term benefit.

Area of Science:

  • Hematology
  • Endocrinology

Context:

  • Antithrombin III (ATIII) deficiency is a rare condition increasing thrombotic risk.
  • Sporadic ATIII deficiency lacks familial history or identifiable acquired causes.
  • Danazol, a synthetic androgen, is known to affect protease levels.

Purpose:

  • To investigate the effect of Danazol on antithrombin III levels in sporadic deficiency.
  • To assess the duration of ATIII level increase after Danazol treatment cessation.

Summary:

  • Seven subjects with sporadic antithrombin III deficiency received Danazol (200 mg TID for 10 days).
  • A mean 21.2% increase in antithrombin III levels was observed.
  • Unlike familial cases, ATIII levels remained elevated post-treatment, with a slight further rise.

Related Experiment Videos

Impact:

  • Danazol may offer a therapeutic option for sporadic antithrombin III deficiency.
  • The sustained elevation suggests potential long-term benefits beyond the treatment period.
  • Further research is warranted to confirm these findings and long-term effects.